Page 16 - உயிரி தொழில்நுட்பவியல் �: AMP

60 Biggest Movers From Yesterday

Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday. Flywire Corporation (NASDAQ: FLYW) gained 46.3% to settle at $35.10 after the company priced its IPO at $24 per share. Build-A-Bear Workshop, Inc. (NYSE: BBW) rose 39.3% to close at $14.07 after the company reported better-than-expected Q1 results and raised FY21 EBITDA guidance. Owens & Minor, Inc. (NYSE: OMI) climbed 36.2% to close at $44.12 on Wednesday..

United statesTimothy springerScopus biopharmaHoldings incScopus biopharma incRanpak holdings corpLipocine incUcloudlink group incCommunity bancorpBiotechnology corporationNewegg commerce incMarine holdings incPonce bank mutual holding companyOndas holdings incAbercrombie fitch coLoserslarimar therapeutics inc

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDeanne randolphpds biotechphoneAmanda hollingerLaurenv woodNational cancer instituteUniversity of texas md anderson cancer centerDrug administrationBiotechnology corporationBiotechnology corporation the companyUnited states securities exchangeNeck cancer allianceBiotechnology corporation nasdaqWall streetChief medical officerExecutive directorCancer center

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs

Pfizer, Inc. (NYSE: PFE) and Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June. Pfizer shares edged down 0.15% to $38.86 in after-hours trading and Myovant receded 0.34% to $23.60. Zosano Announces Publication Of Positive Results From Long-Term Use Of Migraine Drug Zosano Pharma Corporation (NASDAQ: ZSAN) announced that an article titled, Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine was published in the Journal of Headache and Pain

United statesTimothy springerAscendis pharmaAlex kellyAnpac bioPeter traberScience co ltdBiotechnology corporationOcugen incRedhill biopharma ltdPfizer incAbbvie incFite biopharma ltdSingular genomics systems incBausch health to reduce debtTeva pharmaceutical industries limited

Page 16 - உயிரி தொழில்நுட்பவியல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Contract Dose Manufacturing Market Is in Huge Demand | WuXi AppTech, Lonza, Catalent, Siegfried, Recipharm

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) - The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq

60 Biggest Movers From Yesterday

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABBV) - The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs